ECO POWER

Primær information

  • Handelsnavn:
  • ECO POWER (913416)
  • Brugt til:
  • Mennesker
  • Medicin typen:
  • Medicinsk udstyr

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

Lokation

  • Fås i:
  • ECO POWER (913416)
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • Ecolab
  • Autorisationsnummer:
  • 114646E
  • Sidste ændring:
  • 12-03-2018

Produktresumé

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr.

1907/2006

Eco Power

114646E

1 / 12

PUNKT 1. IDENTIFIKATION AF STOFFET/ BLANDINGEN OG AF SELSKABET/ VIRKSOMHEDEN

1.1 Produktidentifikator

Produktnavn

Eco Power

Produkt kode

114646E

Anvendelse af stoffet/det

kemiske produkt

Maskinopvaskemiddel

Stoftype

Blanding

Kun til erhvervsmæssig brug.

Information om fortyndning

Ingen information om fortyndning angivet.

1.2 Relevante identificerede anvendelser for stoffet eller blandingen samt anvendelser, der

frarådes

Identificerede anvendelser

Opvaske- og afspændingsmiddel; Automatisk proces

Anbefalede begrænsninger i

brugen

Forbeholdt industriel og erhvervsmæssig brug.

1.3 Nærmere oplysninger om leverandøren af sikkerhedsdatabladet

Firma

Ecolab ApS

Høffdingsvej 36

2500 Valby, Danmark Tel +45 36 15 85 85

dk-customerservice@ecolab.com

1.4 Nødtelefon

Nødtelefon

36 15 85 85 (hverdage 8.00 - 16.00)

Giftinformationen tlf. nr.

82 12 12 12

Udstedelse-/revisionsdato

17.02.2016

Udgave

PUNKT 2. FAREIDENTIFIKATION

2.1 Klassificering af stoffet eller blandingen

Klassificering (FORORDNING (EF) Nr. 1272/2008)

Hudætsning, Kategori 1A

H314

Alvorlig øjenskade, Kategori 1

H318

Klassificering (67/548/EØF, 1999/45/EF)

C; ÆTSENDE

Se afsnit 16 for fuld ordlyd af R-sætninger nævnt i dette afsnit.

For den fuldstændige tekst af faresætningerne nævnt i dette punkt, se punkt 16.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

2 / 12

2.2 Mærkningselementer

Etikettering (FORORDNING (EF) Nr. 1272/2008)

Farepiktogrammer

Signalord

Fare

Faresætninger

H314

Forårsager svære forbrændinger af huden og

øjenskader.

Sikkerhedssætninger

Forebyggelse:

P280

Bær beskyttelseshandsker/ øjenbeskyttelse/

ansigtsbeskyttelse.

Reaktion:

P303 + P361 + P353

VED KONTAKT MED HUDEN (eller

håret): Alt tilsmudset tøj tages straks af.

Skyl/brus huden med vand.

P305 + P351 + P338

VED KONTAKT MED ØJNENE: Skyl

forsigtigt med vand i flere minutter. Fjern

eventuelle kontaktlinser, hvis dette kan gøres

let. Fortsæt skylning.

P310

Ring omgående til en

GIFTINFORMATION/læge.

Farebestemmende komponent(er) for etikettering:

natriumhydroxid

2.3 Andre farer

Ingen kendte.

PUNKT 3. SAMMENSÆTNING AF/ OPLYSNING OM INDHOLDSSTOFFER

3.2 Blandinger

Farlige komponenter

Kemisk betegnelse

CAS-Nr.

EF-Nr.

REACH No.

Klassificering

(67/548/EØF)

Klassificering

(FORORDNING (EF) Nr.

1272/2008)

Koncentration

natriumhydroxid

1310-73-2

215-185-5

01-2119457892-27

C; R35

Hudætsning Kategori 1A;

H314

Metalætsende Kategori 1;

H290

>= 50 - <= 100

Se afsnit 16 for fuld ordlyd af R-sætninger nævnt i dette afsnit.

For den fuldstændige tekst af faresætningerne nævnt i dette punkt, se punkt 16.

PUNKT 4. FØRSTEHJÆLPSFORANSTALTNINGER

4.1 Beskrivelse af førstehjælpsforanstaltninger

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

3 / 12

I tilfælde af øjenkontakt

Skyl straks med rigeligt vand, også under øjenlågene i mindst 15

minutter. Fjern eventuelle kontaktlinser, hvis dette kan gøres let.

Fortsæt skylning. Søg omgående læge.

I tilfælde af hudkontakt

Vask straks med rigeligt vand i mindst 15 minuter. Brug mild sæbe

hvis tilgængelig. Vask forurenet tøj før genbrug. Rengør grundigt

skoene før genbrug. Søg omgående læge.

Ved indtagelse.

Skyl munden med vand. Fremprovoker IKKE opkastning. Giv

aldrig en bevidstløs person noget gennem munden. Søg

omgående læge.

Hvis det indåndes

Søg frisk luft. Behandles symptomatisk. Søg læge hvis symptomer

opstår.

4.2 Vigtigste symptomer og virkninger, både akutte og forsinkede

I afsnit 11 findes mere detaljerede oplysninger om helbredspåvirkninger og symptomer.

4.3 Angivelse af om øjeblikkelig lægehjælp og særlig behandling er nødvendig

Behandling

Behandles symptomatisk.

PUNKT 5. BRANDBEKÆMPELSE

5.1 Slukningsmidler

Egnede slukningsmidler

Brandslukningsforanstaltningerne skal være hensigtsmæssige i

forhold til lokale omstændigheder og det omgivne miljø.

Uegnede slukningsmidler

Ingen kendte.

5.2 Særlige farer i forbindelse med stoffet eller blandingen

Specifikke farer ved

brandbekæmpelse

Ikke brandfarligt eller brændbart.

Farlige

forbrændingsprodukter

Nedbrydningsprodukter kan omfatte de følgende materialer:

Carbonoxider

Nitrogenoxider (NOx)

Svovloxider

Fosforholdige oxider

5.3 Anvisninger for brandmandskab

Særlige personlige

værnemidler, der skal bæres

af brandmandskabet

: Brug personligt beskyttelsesudstyr.

Yderligere oplysninger

: Brandrester og forurenet brandslukningsvand skal bortskaffes i

henhold til de lokale regler. Indånd ikke dampe i tilfælde af brand

og/eller eksplosion.

PUNKT 6. FORHOLDSREGLER OVER FOR UDSLIP VED UHELD

6.1 Personlige sikkerhedsforanstaltninger, personlige værnemidler og nødprocedurer

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

4 / 12

Rådgivning for ikke-

indsatspersonel

Sørg for tilstrækkelig ventilation. Hold personer borte fra og imod

vindretningen i forhold til spild/lækage. Undgå indånding,

indtagelse og kontakt med hud og øjne. Hvis medarbejdere

udsættes for koncentrationer over grænseværdien skal de benytte

egnede godkendte åndedrætsværn. Sørg for, at rengøring kun

udføres at uddannet personale. Der henvises til

beskyttelsesforanstaltninger nævnt i afsnit 7 og 8.

Rådgivning for

indsatspersonel

Hvis særlig beklædning er påkrævet for at håndtere spildet, skal

man være opmærksom på alle oplysninger i punkt 8 om passende

og upassende materialer.

6.2 Miljøbeskyttelsesforanstaltninger

Miljøbeskyttelsesforanstaltnin

Tillad ikke kontakt med jord, overflade- eller grundvand.

6.3 Metoder og udstyr til inddæmning og oprensning

Metoder til oprydning

Fej op og skovl op i egnede affaldsbeholdere.

6.4 Henvisning til andre punkter

Se Afsnit 1 for kontaktoplysninger i nødsituationer.

For personlig beskyttelse se punkt 8.

Se Afsnit 13 for yderligere oplysninger om affaldshåndtering.

PUNKT 7. HÅNDTERING OG OPBEVARING

7.1 Forholdsregler for sikker håndtering

Råd om sikker håndtering

Må ikke sluges. Må ikke komme i kontakt med øjne, hud eller tøj.

Indånd ikke pulver/ røg/ gas/ tåge/ damp/ spray. Brug kun med

tilstrækkelig ventilation. Vask hænder grundigt efter brug.

Hygiejniske foranstaltninger

Skal håndteres i overensstemmelse med god erhvervshygiejne og

sikkerhedsforanstaltninger. Fjern forurenet tøj og vask før

genbrug. Vask ansigt, hænder og alt udsat hud grundigt efter

brug. Ved kontakt eller risiko for stænk, sørg for at der forefindes

nødbruser eller andet udstyr til skyldning af øjne og krop.

7.2 Betingelser for sikker opbevaring, herunder eventuel uforenelighed

Krav til lager og beholdere

Opbevares utilgængeligt for børn. Hold beholderen tæt lukket.

Opbevares i behørigt mærkede beholdere.

Opbevaringstemperatur

0 °C til 40 °C

7.3 Særlige anvendelser

Særlige anvendelser

Opvaske- og afspændingsmiddel; Automatisk proces

PUNKT 8. EKSPONERINGSKONTROL/PERSONLIGE VÆRNEMIDLER

8.1 Kontrolparametre

Grænseværdier for erhvervsmæssig eksponering

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

5 / 12

Komponenter

CAS-Nr.

Ventil type

(Påvirkningsform)

Kontrolparametre

Basis

natriumhydroxid

1310-73-2

2 mg/m3

DK OEL

DNEL

Natriumhydroxid

Anvendelse: Arbejdstagere

Eksponeringsvej: Indånding

Potentielle sundhedseffekter: Langtids lokale effekter

Værdi: 1 mg/m3

Anvendelse: Forbrugere

Eksponeringsvej: Indånding

Potentielle sundhedseffekter: Langtids lokale effekter

Værdi: 1 mg/m3

8.2 Eksponeringskontrol

Passende tekniske foranstaltninger

Tekniske foranstaltninger

Effektivt udsugningssystem. Hold luftkoncentrationerne under

erhvervsmæssige eksponeringsstandarder.

Individuelle beskyttelsesforanstaltninger

Hygiejniske foranstaltninger

Skal håndteres i overensstemmelse med god erhvervshygiejne og

sikkerhedsforanstaltninger. Fjern forurenet tøj og vask før

genbrug. Vask ansigt, hænder og alt udsat hud grundigt efter

brug. Ved kontakt eller risiko for stænk, sørg for at der forefindes

nødbruser eller andet udstyr til skyldning af øjne og krop.

Beskyttelse af øjne / ansigt

(EN 166)

Beskyttelsesbriller

Ansigtsskærm

Beskyttelse af hænder (EN

374)

Anbefalet forbyggende hudbeskyttelse

Handsker

Nitrilgummi

butylgummi

Gennemtrængningstid: 1-4 timer

Søg vejledning hos PPE producent for den passende

handsketykkelse (afhængigt af hvilken type handske og dens

påtænkte anvendelse).

Handsker skal bortskaffes og erstattes hvis der er nogen som

helst indikation af nedbrydning eller kemisk gennembrud.

Beskyttelse af hud og krop

(EN 14605)

Personligt beskyttelsesudstyr bestående af: egnede

beskyttelseshandsker, sikkerhedsbriller og beskyttelsesdragt

Åndedrætsværn (EN 143,

14387)

Når respiratoriske risici ikke kan undgås eller i tilstrækkelig grad

begrænses ved kollektive tekniske beskyttelsesforanstaltninger,

eller ved foranstaltninger, metoder eller procedurer for

tilrettelæggelse af arbejdet, overvej da brugen af certificeret

åndedrætsværn som opfylder EU-krav (89/656 / EØF, 89/686 /

EØF) eller tilsvarende, med filtertype:

Foranstaltninger til begrænsning af eksponering af miljøet

Generelle anvisninger

: Overvej om det er nødvendig at lukke opbevaringsbeholderne

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

6 / 12

inde.

PUNKT 9. FYSISKE OG KEMISKE EGENSKABER

9.1 Oplysninger om grundlæggende fysiske og kemiske egenskaber

Udseende

: fast

Farve

: lysegul

Lugt

: lugtfri

pH-værdi

10.0 - 12.0, 1 %

Flammepunkt

Ikke anvendelig

Lugttærskel

Ikke anvendelig og/eller ikke bestemt for blandingen

Smeltepunkt/frysepunkt

Ikke anvendelig og/eller ikke bestemt for blandingen

Begyndelseskogepunkt og

kogepunktsinterval

Ikke anvendelig og/eller ikke bestemt for blandingen

Fordampningshastighed

Ikke anvendelig og/eller ikke bestemt for blandingen

Antændelighed (fast stof,

luftart)

Ikke anvendelig og/eller ikke bestemt for blandingen

Højeste eksplosionsgrænse

Ikke anvendelig og/eller ikke bestemt for blandingen

Laveste eksplosionsgrænse

Ikke anvendelig og/eller ikke bestemt for blandingen

Damptryk

Ikke anvendelig og/eller ikke bestemt for blandingen

Relativ dampvægtfylde

Ikke anvendelig og/eller ikke bestemt for blandingen

Relativ massefylde

1.4 - 1.6

Vandopløselighed

opløselig

Opløselighed i andre

opløsningsmidler

Ikke anvendelig og/eller ikke bestemt for blandingen

Fordelingskoefficient: n-

oktanol/vand

Ikke anvendelig og/eller ikke bestemt for blandingen

Selvantændelsestemperatur

Ikke anvendelig og/eller ikke bestemt for blandingen

Termisk spaltning

Ikke anvendelig og/eller ikke bestemt for blandingen

Viskositet, kinematisk

Ikke anvendelig og/eller ikke bestemt for blandingen

Eksplosive egenskaber

Ikke anvendelig og/eller ikke bestemt for blandingen

Oxiderende egenskaber

Stoffet eller blandingen er ikke klassificeret som oxiderende.

9.2 Andre oplysninger

Ikke anvendelig og/eller ikke bestemt for blandingen

PUNKT 10. STABILITET OG REAKTIVITET

10.1 Reaktivitet

Ingen farlige reaktioner kendt ved normalt brug under normale forhold.

10.2 Kemisk stabilitet

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

7 / 12

Stabil under normale forhold.

10.3 Risiko for farlige reaktioner

Ingen farlige reaktioner kendt ved normalt brug under normale forhold.

10.4 Forhold, der skal undgås

Ingen kendte.

10.5 Materialer, der skal undgås

Syrer

10.6 Farlige nedbrydningsprodukter

Nedbrydningsprodukter kan omfatte de følgende materialer:

Carbonoxider

Nitrogenoxider (NOx)

Svovloxider

Fosforholdige oxider

PUNKT 11. TOKSIKOLOGISKE OPLYSNINGER

11.1 Oplysninger om toksikologiske virkninger

Oplysninger om sandsynlige

eksponeringsveje

Øjenkontakt, Hudkontakt

Toksicitet

Akut oral toksicitet

: Der er ingen tilgængelige data på dette produkt.

Akut toksicitet ved indånding

: Der er ingen tilgængelige data på dette produkt.

Akut dermal toksicitet

: Der er ingen tilgængelige data på dette produkt.

Hudætsning/-irritation

: Der er ingen tilgængelige data på dette produkt.

Alvorlig

øjenskade/øjenirritation

: Der er ingen tilgængelige data på dette produkt.

Respiratorisk sensibilisering

eller hudsensibilisering

: Der er ingen tilgængelige data på dette produkt.

Kræftfremkaldende

egenskaber

: Der er ingen tilgængelige data på dette produkt.

Reproduktionsskadende

virkninger

: Der er ingen tilgængelige data på dette produkt.

Kimcellemutagenicitet

: Der er ingen tilgængelige data på dette produkt.

Fosterbeskadigelse

: Der er ingen tilgængelige data på dette produkt.

Enkel STOT-eksponering

: Der er ingen tilgængelige data på dette produkt.

Gentagne STOT-

: Der er ingen tilgængelige data på dette produkt.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

8 / 12

eksponeringer

Aspiration giftighed

: Der er ingen tilgængelige data på dette produkt.

Potentielle sundhedspåvirkninger

Øjne

Forårsager alvorlig øjenskade.

Medfører alvorlige hudforbrændinger.

Indtagelse

Forårsager ætsninger i fordøjelseskanalen.

Indånding

Kan medføre næse, hals og lunge irritation.

Langtidspåvirkning

Helbredsskader er ikke kendte eller forventede ved normalt brug.

Erfaringer med human eksponering

Øjenkontakt

Rødme, Smerte, Ætsning

Hudkontakt

Rødme, Smerte, Ætsning

Indtagelse

Ætsning, Mavesmerter

Indånding

Åndedrætsirritation, Hoste

PUNKT 12. MILJØOPLYSNINGER

12.1 Økotoksicitet

Miljøpåvirkninger

Dette produkt har ingen kendt økotoksikologisk effekt.

Produkt

Toksicitet overfor fisk

: Ingen data tilgængelige

Toksicitet for dafnier og

andre hvirvelløse vanddyr.

: Ingen data tilgængelige

Toksicitet overfor alger

: Ingen data tilgængelige

Komponenter

Toksicitet for dafnier og

andre hvirvelløse vanddyr.

: natriumhydroxid

48 h EC50: 40 mg/l

12.2 Persistens og nedbrydelighed

Produkt

Biologisk nedbrydelighed

: Tensiderne i produktet er biologisk nedbrydelige iht. kravene i

forordning nr. 648/2004 om vaske- og rengøringsmidler.

Komponenter

Biologisk nedbrydelighed

natriumhydroxid

Resultat: Ikke anvendelig - uorganisk

12.3 Bioakkumuleringspotentiale

Ingen data tilgængelige

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

9 / 12

12.4 Mobilitet i jord

Ingen data tilgængelige

12.5 Resultater af PBT- og vPvB-vurdering

Produkt

Vurdering

Dette stof/blanding indeholder ingen komponenter, der anses for

at være enten persistente, bioakkumulerende og toksiske (PBT)

eller meget persistente og meget bioakkumulerende (vPvB) ved

niveauer på 0.1% eller højere.

12.6 Andre negative virkninger

Ingen data tilgængelige

PUNKT 13. BORTSKAFFELSE

Bortskaffes i overensstemmelse med EU-direktiverne om affald og farligt affald.Affaldskoder skal

fastsættes af bruger, at fortrække i samarbejde med de myndigheder der er ansvarlig for

bortskaffelse af affald.

13.1 Metoder til affaldsbehandling

Produkt

: Hvor det er muligt foretrækkes genanvendelse frem for

bortskaffelse eller forbrænding. Hvis genanvendelse ikke er

praktisk muligt, skal bortskaffelse ske i henhold til lokale

regulativer. Bortskaf affald til en godkendt

affaldsbortskaffelsesfacilitet.

Forurenet emballage

: Bortskaffes som ikke-forarbejdet produkt. Tomme beholdere skal

bringes til et godkendt affaldsdeponeringssted for genbrug eller

bortskaffelse. Tomme beholdere må ikke genbruges. Bortskaffes i

overensstemmelse med lokale, regionale og nationale

bestemmelser.

Europæisk Affalds Katalog

: 200115* - Baser

PUNKT 14. TRANSPORTOPLYSNINGER

Afsenderen har ansvar for, at emballager, etikettering og mærkning er i overensstemmelse med den

valgte transportform.

Vejtransport (ADR/ADN/RID)

14.1 FN-nummer

1823

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

NATRIUMHYDROXID, FAST

14.3 Transportfareklasse( r )

14.4 Emballagegruppe

14.5 Miljøfarer

14.6 Særlige

forsigtighedsregler for

brugeren

Ingen

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

10 / 12

Lufttransport (IATA)

14.1 FN-nummer

1823

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

Sodium hydroxide, solid

14.3 Transportfareklasse( r )

14.4 Emballagegruppe

14.5 Miljøfarer

14.6 Særlige

forsigtighedsregler for

brugeren

Ingen

Søtransport (IMDG/IMO)

14.1 FN-nummer

1823

14.2 UN-

forsendelsesbetegnelse (UN

proper shipping name)

SODIUM HYDROXIDE, SOLID

14.3 Transportfareklasse( r )

14.4 Emballagegruppe

14.5 Miljøfarer

14.6 Særlige

forsigtighedsregler for

brugeren

Ingen

14.7 Bulktransport i henhold

til bilag II til MARPOL 73/78

og IBC-koden

Ikke anvendelig

PUNKT 15. OPLYSNINGER OM REGULERING

15.1 Særlige bestemmelser/særlig lovgivning for stoffet eller blandingen med hensyn til

sikkerhed, sundhed og miljø

iht. Detergent Forordningen

EU 648/2004

5 % eller derover men under 15 %: Polycarboxylater

under 5 %: Fosfonater, Nonioniske overfladeaktive stoffer

National lovgivning

Vær opmærksom på Dir 94/33/EF til beskyttelse af unge mennesker på arbejde.

Anvendelsesbegrænsninger for unge under 18, jf. BEK nr 239 af 06/04/2005 Bekendtgørelse om

unges arbejde (Ungebekendtgørelsen).

Anvendelsesbegrænsninger for unge under 18, jf. BEK nr 239 af 06/04/2005 Bekendtgørelse om

unges arbejde (Ungebekendtgørelsen).

15.2 Kemikaliesikkerhedsvurdering

Produktet indeholder stoffer, for hvilke der fortsat kræves en kemisk sikkerhedsvurdering.

PUNKT 16. ANDRE OPLYSNINGER

Fuld tekst af R-sætninger

Alvorlig ætsningsfare.

Fuld tekst af H-sætninger

H290

Kan ætse metaller.

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

11 / 12

H314

Forårsager svære forbrændinger af huden og øjenskader.

Fuld tekst af andre forkortelser

ADN - Europæisk konvention om international transport af farligt gods ad indre vandveje; ADR -

Europæisk konvention om international transport af farligt gods ad vej; AICS - Australiens

fortegnelse over kemiske stoffer; ASTM - Det amerikanske forbund for testning af materialer,

ASTM; bw - Kropsvægt; CLP - CLP-forordningen om klassificering, mærkning og emballering;

Forordning (EF) Nr. 1272/2008; CMR - Kræftfremkaldende, mutagent eller reproduktionstoksisk

stof; DIN - Standard fra det tyske standardiseringsinstitut; DSL - Liste over indenlandske stoffer

(Canada);

ECHA

europæiske

kemikalieagentur;

EC-Number

EU-nummer;

Koncentration forbundet med x % respons; ELx - Belastningsgrad forbundet med x % respons;

EmS - Nødplan; ENCS - Eksisterende og nye kemiske stoffer (Japan); ErCx - Koncentration

forbundet med x % vækstrate respons; GHS - Det globale harmoniserede system; GLP - God

laboratoriepraksis;

IARC

Internationale

Agentur

Kræftforskning;

IATA

Internationale Luftfartssammenslutning, IATA; IBC - Den internationale kode for konstruktion og

udrustning af skibe, som fører farlige kemikalier i bulk; IC50 - Halv maksimal inhiberende

koncentration; ICAO - Organisationen for International Civil Luftfart, ICAO; IECSC - Fortegnelse

over eksisterende kemikalier i Kina; IMDG - Det internationale regelsæt for søtransport af farligt

gods; IMO - Den Internationale Søfartsorganisation; ISHL - Lov om industriel sikkerhed og

sundhed (Japan); ISO - International standardiseringsorganisation; KECI - Koreas fortegnelse

over eksisterende kemikalier; LC50 - Dødelig koncentration for 50 % af en testpopulation; LD50 -

Dødelig dosis for 50 % af en testpopulation (gennemsnitlig dødelig dosis); MARPOL - Den

internationale konvention om forebyggelse af forurening fra skibe; n.o.s. - Andet ikke angivet;

NO(A)EC - Koncentration for ingen observeret (negativ) virkning; NO(A)EL - Niveau for ingen

observeret (negativ) virkning; NOELR - Belastningsgrad for ingen observeret virkning; NZIoC -

New Zealands fortegnelse over kemikalier; OECD - Organisationen for Økonomisk Samarbejde

og Udvikling; OPPTS - Afdelingen for kemisk sikkerhed og forebyggelse af forurening; PBT -

Persistent, bioakkumulativt og giftigt stof; PICCS - Fillippinernes fortegnelse over kemikalier og

kemiske stoffer; (Q)SAR - (Kvantitativt) forhold mellem struktur og aktivitet; REACH - Europa-

parlamentets og Rådets forordning (EF) nr. 1272/2008 om registrering, vurdering og godkendelse

af samt begrænsninger for kemikalier; RID - Reglement for international befordring af farligt gods

med jernbane; SADT - Selvaccelererende dekompositionstemperatur; SDS - Sikkerhedsdatablad;

TCSI - Taiwans fortegnelse over kemiske stoffer; TRGS - Teknisk forskrift for farlige stoffer; TSCA

- Lov om kontrol af giftige stoffer (USA); UN - Forenede Nationer; vPvB - Meget persistent og

meget bioakkumulativ

Udarbejdet af

Regulatory Affairs

Tal angives i sikkerhedsdatabladet i følgende form: 1,000,000 = 1 million og 1,000 = 1 tusind. 0.1

= 1 tiendedel og 0.001 = 1 tusindedel.

REVIDERET INFORMATION: Signifikante ændringer i den regulatoriske eller sundhedsmæssige

information af denne revision er angivet med en lodret streg i sikkerhedsdatabladets venstre

margin.

Informationerne i dette Arbejdshygiejniske Datablad er efter vor bedste viden, oplysninger og

overbevisning korrekte på datoen, hvor det er trykt. Informationerne tjener kun som vejledning til

sikker håndtering, brug, forarbejdning, lagring, transport, disponering og frigivelse og kan ikke

betragtes som en garanti eller kvalitetsangivelse. Informationerne vedrører kun det udtrykkeligt

angivne materiale og er ikke gældende for dette materiale anvendt i kombination med andre

materialer eller forarbejdning, medmindre udtrykkeligt anført i teksten.

BILAG: EKSPONERINGSSCENARIER

DPD+-stoffer

:

SIKKERHEDSDATABLAD

i henhold til Forordning (EF) nr. 1907/2006

Eco Power

114646E

12 / 12

Følgende stoffer er de vigtigste stoffer der bidrager til blandingens eksponeringsscenarie i henhold

til DPD+-regelen:

Måde for

optagelse

Stof

CAS-Nr.

EINECS-Nr.

Indtagelse

natriumhydroxid

1310-73-2

215-185-5

Indånding

natriumhydroxid

1310-73-2

215-185-5

natriumhydroxid

1310-73-2

215-185-5

Øjne

natriumhydroxid

1310-73-2

215-185-5

vandmiljø

Ikke afhængighedsstof

Fysikaliske egenskaber DPD+-stoffer:

Stof

Damptryk

Vandopløselighe

d

Pow

Molar masse

natriumhydroxid

1 g/ml

40 g/mol

For at beregne om anvendelsesforholdene og de nødvendige risikohåndteringsforanstaltninger

er sikre, venligst kalkuler risikofaktor på dette web site:

www.ecetoc.org/tra

Eksponeringsscenariets korte

titel

Opvaske- og afspændingsmiddel; Automatisk proces

Use descriptors

Hovedbrugergrupper

Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Slutanvendelsessektor

SU22: Faglige anvendelser: Det offentlige område (administration,

uddannelse, forlystelser, tjeneste-ydelser, håndværkere)

Proceskategorier

PROC2: Anvendelse i lukket, kontinuerlig proces med kontrolleret

lejlighedsvis eksponering

PROC8b: Overførsel af stof eller kemisk produkt (påfyldning/

tømning) fra/ til kar/ store beholdere på dedikerede anlæg

Produktkategorier

PC35: Vaske- og renseprodukter (herunder opløsnings-

middelbaserede produkter)

Miljøudledningskategorier

ERC8a: Udbredt indendørs anvendelse af proceshjælpemidler i

åbne systemer

  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.



  • Dokumenter på andre sprog er tilgængelige her

20-10-2018

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Scientific Opinion of Flavouring Group Evaluation 411 (FGE.411): 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide from chemical group 30 (miscellaneous substances)

Published on: Fri, 19 Oct 2018 00:00:00 +0200 EFSA was requested to deliver a scientific opinion on the implications for human health of the flavouring substance 2‐(4‐methylphenoxy)‐N‐(1H‐pyrazol‐3‐yl)‐N‐(thiophen‐2‐ylmethyl)acetamide [FL‐no: 16.133], in the Flavouring Group Evaluation 411 (FGE.411), according to Regulation (EC) No 1331/2008 of the European Parliament and of the Council. The substance has not been reported to occur in natural source materials of botanical or animal origin. It is intende...

Europe - EFSA - European Food Safety Authority Publications

18-10-2018

CTG recalls Friction Powered School Bus

CTG recalls Friction Powered School Bus

Health Canada's sampling and evaluation program has determined that the school bus toy does not meet Canadian safety requirements for toys. Specifically, the school bus released small parts during testing, which are a choking hazard for young children.

Health Canada

11-10-2018

Cooper Lighting LLC Recalls All-Pro and Defiant Solar/Battery Powered Light Fixtures

Cooper Lighting LLC Recalls All-Pro and Defiant Solar/Battery Powered Light Fixtures

The batteries in the solar-powered light fixtures can overheat and cause the light fixture's housing to melt, posing a fire hazard.

Health Canada

11-10-2018

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Re‐evaluation of oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (E 479b) as a food additive

Published on: Wed, 10 Oct 2018 00:00:00 +0200 The EFSA Panel on Food Additives and Flavourings (FAF) provides a scientific opinion re‐evaluating the safety of thermally oxidised soya bean oil interacted with mono‐ and diglycerides of fatty acids (TOSOM) (E 479b) when used as a food additive. The Scientific Committee on Food (SCF) and the Joint FAO/WHO Expert Committee on Food Additives (JECFA) derived an acceptable daily intake (ADI) of 25 and 30 mg/kg body weight (bw) per day, respectively. There was n...

Europe - EFSA - European Food Safety Authority Publications

25-9-2018

Daiso Holdings Ltd. recalls Daiso Brand Consumer Chemical Products

Daiso Holdings Ltd. recalls Daiso Brand Consumer Chemical Products

The recalled products have not been properly classified according to the Consumer Chemicals and Containers Regulations, 2001, in order to ensure appropriate hazard labelling. These regulations are empowered by the Canada Consumer Product Safety Act. Improper labelling could result in unintentional exposure to these products and lead to serious illness, injury or death.

Health Canada

21-9-2018

Scientific guideline:  Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

Scientific guideline: Guideline on determination of withdrawal periods for edible tissues - Revision 1, adopted

This document provides a standard approach to be used across the European Union in the analysis of residue depletion data for the purpose of establishing withdrawal periods for edible tissues. Emphasis has been put on a statistical approach. As the method of first choice, a linear regression technique is recommended. A computerised version of the method described is available: Updated application software: withdrawal time calculation for tissues. Read together with the explanatory note on updated applica...

Europe - EFSA - European Food Safety Authority EFSA Journal

18-9-2018

Xtava recalls Allure and Allure Pro 2200W ionic ceramic hair dryers

Xtava recalls Allure and Allure Pro 2200W ionic ceramic hair dryers

The hair dryer and power cord can overheat and catch on fire, posing fire, burn and electrical shock hazards.

Health Canada

18-9-2018

EFSA conference opens with call to harness the ‘power of collaboration’

EFSA conference opens with call to harness the ‘power of collaboration’

EFSA conference opens with call to harness the ‘power of collaboration’

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

12-9-2018

Natural Disaster Preparedness and Response (Drugs)

Natural Disaster Preparedness and Response (Drugs)

The FDA reminds consumers to have an emergency plan and to take precautions for storing water and ensuring the safety of their food and medical supplies for themselves and their pets during and after severe storms (tornados, hurricanes, blizzards) and other events that can result in power outages, flooding, or road and business closures.

FDA - U.S. Food and Drug Administration

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Risk assessment of antimicrobial resistance along the food chain through culture‐independent methodologies

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Antimicrobial resistance (AMR) represents a major challenge for Public Health and the scientific community, and requires immediate and drastic solutions. Acquired resistance to certain antimicrobials is already widespread to such an extent that their efficacy in the treatment of certain life‐threatening infections is already compromised. To date, the emergence and spread of AMR has been attributed to the use, misuse or indiscriminate use of antibiotics as th...

Europe - EFSA - European Food Safety Authority Publications

31-8-2018

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Alcon Announces Voluntary Global Market Withdrawal of CyPass Micro-Stent for Surgical Glaucoma

Reflecting its uncompromising commitment to patient safety, Alcon today announced an immediate, voluntary market withdrawal of the CyPass Micro-Stent from the global market. In addition, Alcon advises surgeons to immediately cease further implantation with the CyPass Micro-Stent and to return any unused devices to Alcon. This decision and corresponding recommendation is based on an analysis of five-year post-surgery data from the COMPASS-XT long-term safety study. The US Food and Drug Administration (FD...

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Scientific Opinion about the Guidance of the Chemical Regulation Directorate (UK) on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessments

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The EFSA Panel on Plant Protection Products and their Residues reviewed the guidance on how aged sorption studies for pesticides should be conducted, analysed and used in regulatory assessment. The inclusion of aged sorption is a higher tier in the groundwater leaching assessment. The Panel based its review on a test with three substances taken from a data set provided by the European Crop Protection Association. Particular points of attention were the quali...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Joint EFSA and ECDC 2018 workshop on preparedness for a multi‐national food safety/public health incident

Published on: Tue, 21 Aug 2018 00:00:00 +0200 Abstract In May 2018, EFSA and ECDC co‐facilitated a workshop on preparedness for a multi‐national food safety/public health incident. The workshop, hosted at AGES in Vienna, was conceived to closely align with EFSA's Strategy 2020 commitment to prepare for future risk assessment challenges. EFSA, ECDC, AGES and BfR worked together closely to develop a workshop and associated training materials to be delivered over a 2.5‐day agenda. The workshop was attended...

Europe - EFSA - European Food Safety Authority Publications

29-8-2018

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Strategic partnership with German data providing institutions on data quality (Pilot project) – Final report

Published on: Tue, 07 Aug 2018 00:00:00 +0200 This report describes the framework of collection, management and transmission of food safety data in the Federal Republic of Germany. To adjust optimally the data governance processes to the requirements defined by the EFSA, measures had been agreed upon in order to improve the specified situation. Subsequent methodological system enhancements related to data quality are given as well as structural adjustments and the development and implementation of suppo...

Europe - EFSA - European Food Safety Authority Publications

28-8-2018

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

New recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones

The EU's Pharmacovigilance Risk Assessment Committee (PRAC) has adopted new recommendations for use of Xofigo for treatment of prostate cancer which has spread to the bones (bone metastases). Xofigo should only be used in symptomatic patients who have had two previous treatments for prostate cancer and who cannot be treated with other medicines.

Danish Medicines Agency

24-8-2018

Imagine recalls Buckyballs magnet sets

Imagine recalls Buckyballs magnet sets

Health Canada has determined that these magnet sets are a danger to human health and safety because they contain small powerful magnets which can be easily swallowed or inhaled by children. Unlike other small objects that would be more likely to pass normally through the digestive system if swallowed, when more than one small powerful magnet is swallowed, the magnets can attract one another while travelling through the digestive system. The magnets can then pinch together and create a blockage and slowly...

Health Canada

23-8-2018

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Third external evaluation of EFSA – progress made, recommendations for improvement

Europe - EFSA - European Food Safety Authority Press Releases & News Stories

16-8-2018

Zakah Life Recalls Kratom Because Of Possible Health Risk

Zakah Life Recalls Kratom Because Of Possible Health Risk

Zakah Life, LLC of Ankeny, Iowa, is recalling the following Kratom products (Super Green Maeng Da Premium Kratom powder, Powerful Red Vein Bali Premium Kratom powder, Super Green Maeng Da Premium Kratom capsules, and Powerful Red Vein Bali Premium Kratom capsules) with expiration dates prior to 01/01/2023 because they have the potential of being contaminated with Salmonella, an organism which can cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weak...

FDA - U.S. Food and Drug Administration

7-8-2018

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Seaweed consumption: remain vigilant to the risk of excess iodine intake

Over the last few years, seaweed has become increasingly common on our plates. Fresh, dried or as a food supplement, its iodine content varies and can sometimes be high. ANSES assessed the risk of excess iodine intake from the consumption of seaweed-based products. In view of the non-negligible risk of exceeding the upper limit of safe intake for iodine, the Agency advises against the consumption of seaweed and seaweed-based food supplements by certain at-risk populations, and recommends that regular con...

France - Agence Nationale du Médicament Vétérinaire

6-8-2018

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA takes new steps to encourage the development of novel medicines for the treatment of opioid use disorder

FDA issued new scientific recommendations aimed at encouraging more widespread innovation and development of novel medication-assisted treatment drugs to treat opioid use disorder.

FDA - U.S. Food and Drug Administration

30-7-2018

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

ANSES recommends that certain populations avoid the consumption of food supplements containing melatonin

Under the national nutrivigilance scheme, reports of adverse effects likely to be associated with the consumption of food supplements containing melatonin have been brought to the attention of ANSES. A retrospective analysis of these reports, combined with the considerable level of consumption of this type of supplement, led ANSES to conduct an assessment of the potential health risks. In its Opinion of February 2018, the Agency highlighted the existence of populations and situations at risk, for which t...

France - Agence Nationale du Médicament Vétérinaire

20-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s efforts to encourage the development of and broaden access to generic versions of opioid analgesics that are formulated to deter abuse

FDA posted a new batch of 43 product-specific guidances related to the development of generic drug products that includes three revised product-specific guidances for ADF opioid products. These guidances recommend specific in vivo studies and in vitro study considerations for abuse deterrence evaluations.

FDA - U.S. Food and Drug Administration

19-7-2018

Assessment of the safety of feminine hygiene products

Assessment of the safety of feminine hygiene products

Today ANSES is publishing its health risk assessment on the safety of feminine hygiene products. Chemicals have been identified in these products at very low concentrations not exceeding health thresholds. The expert appraisal did not reveal any risk associated with these substances. Nevertheless, the Agency recommends that manufacturers improve the quality of these products in order to eliminate or minimise the presence of chemicals. ANSES’s expert appraisal also examined the risk of menstrual toxic sho...

France - Agence Nationale du Médicament Vétérinaire

18-7-2018

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

&quot;Anti-pollution&quot; masks: not enough data to demonstrate a health benefit and justify recommending their use

In a context where prevention of ambient air pollution is a real public health issue, questions are regularly asked about the value of recommending that the population wear personal protective equipment. This led ANSES to assess the potential health benefits of wearing "anti-pollution" masks. Its expert appraisal revealed a lack of data demonstrating a health benefit. To reduce the health impacts associated with ambient air pollution, the Agency reiterates the importance of prioritising action at the sou...

France - Agence Nationale du Médicament Vétérinaire

17-7-2018

Statement from FDA Commissioner Scott Gottlieb, M.D. on new efforts to empower consumers by advancing access to nonprescription drugs

Statement from FDA Commissioner Scott Gottlieb, M.D. on new efforts to empower consumers by advancing access to nonprescription drugs

FDA describes innovative approaches to increase access to a broader selection of nonprescription drug products for consumers

FDA - U.S. Food and Drug Administration

13-7-2018

Scientific guideline:  Guideline on good pharmacogenomic practice - First version, adopted

Scientific guideline: Guideline on good pharmacogenomic practice - First version, adopted

This guideline provides recommendations for the conduct of genomic studies in relation to medical therapy in order to provide high quality information on the impact of genomic variability on drug response. Primary focus is on the analysis of genomic germline DNA. The analysis of somatic DNA and genomic biomarkers for cancer treatment is not being discussed and might be developed as an Annex or in separate guidance.

Europe - EFSA - European Food Safety Authority EFSA Journal

9-7-2018

Public Notification: Maximum Powerful contains hidden drug ingredient

Public Notification: Maximum Powerful contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use Maximum Powerful, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

4-7-2018

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Footwear and textile clothing: consumers need better protection from the risks of skin allergies and irritation

Cases of skin allergies and irritation related to clothing or footwear are regularly reported to the health authorities. Today ANSES is publishing the results of the expert appraisal it conducted to identify the chemicals likely to be found in these articles and possibly responsible for these cases. Further to this expert appraisal, the Agency is issuing recommendations on how to better protect consumers from the risks of skin allergies and irritation caused by the presence of these substances.

France - Agence Nationale du Médicament Vétérinaire

28-6-2018

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

Ambient air quality: ANSES recommends the surveillance of 1,3-butadiene and the enhanced monitoring of ultrafine particles (UFPs) and carbon black

The European monitoring strategy for air quality relies heavily on quality standards for a number of pollutants. Advances in knowledge on the toxicity of substances and their emissions in the atmosphere have shown that certain pollutants that may have an impact on human health are not currently taken into account in regulatory monitoring. ANSES therefore received a formal request from the Ministries of Ecology and Health to propose a list of new priority pollutants for this air quality monitoring to supp...

France - Agence Nationale du Médicament Vétérinaire

12-6-2018

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

Ashley Furniture Industries , Inc. recalls Signature Design by Ashley Amnon Floor Lamp

The lamp has incorrect lightbulb wattage information printed on a label on the sockets of the lamp. The incorrect labels indicate that each socket can support 40 W bulbs, however the product is only rated for each socket supporting a 25 W bulb. The use of lightbulbs with the incorrect wattage could potentially melt the power-switch, posing a burn hazard.

Health Canada

8-6-2018

Amerisun, Inc. recalls PowerSmart Gas Powered 2 Stage Snow Blowers

Amerisun, Inc. recalls PowerSmart Gas Powered 2 Stage Snow Blowers

If the pulley bolt was not tightened sufficiently during the manufacturing process and did not have threadlocker applied by the manufacturer, the bolt may become loose and could lodge against the drive plate, which will apply pressure to the drive plate and keep the unit in drive.

Health Canada

1-6-2018

HeartWare HVAD System by Medtronic: Class I Recall - Due to Unintended Intermittent Electrical Disconnection between the Power Source and the Controller

HeartWare HVAD System by Medtronic: Class I Recall - Due to Unintended Intermittent Electrical Disconnection between the Power Source and the Controller

Interruptions to the electrical connection could cause a pump stop. A pump stop could cause patient harm such as exacerbation of heart failure symptoms, or symptoms such as mild weakness, loss of consciousness, or death.

FDA - U.S. Food and Drug Administration

8-5-2018

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

Neurovascular Stents Used for Stent-Assisted Coiling (SAC): Letter to Health Care Providers - Recommendations Associated With the Use of These Devices in the Treatment of Unruptured Brain Aneurysms

The FDA has received reports associated with the use of these devices in the treatment of unruptured brain aneurysms that suggest some events of peri-procedural stroke and/or death may have been related to procedural risks or patient selection related factors. These factors include patients who had serious co-morbidities resulting in a reduced life expectancy, or who were intolerant to required anticoagulation or anti-platelet therapy.

FDA - U.S. Food and Drug Administration

20-3-2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

Medicines Safety Update, Volume 9, Number 1, February-March 2018

First-generation oral sedating antihistamines – use in children, Suvorexant (Belsomra) – next day effects, Desvenlafaxine (Pristiq) recommended dose, Miconazole and potential interaction with warfarin

Therapeutic Goods Administration - Australia

15-2-2018

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

Be aware of rare but possible risk of liver injury in medical treatment of fibroids

The Danish Medicines Agency recommends doctors not to start any new patients on the medicine Esmya (ulipristal) because of a rare, but possible, risk of developing serious liver injury.

Danish Medicines Agency

14-11-2017

The European Commission has published three recommendations for the clinical trials regulation

The European Commission has published three recommendations for the clinical trials regulation

In cooperation with the clinical trials expert group, the European Commission is updating and issuing new recommendations as a result of the regulation on clinical trials on medicinal products for human use.

Danish Medicines Agency

7-11-2017

Maximum powerful (Baiwei USA) tablets

Maximum powerful (Baiwei USA) tablets

Safety Alert - Maximum Powerful (Baiwei USA) tablets

Therapeutic Goods Administration - Australia

21-3-2017

New recommendation for phasing out zinc oxide for young pigs

New recommendation for phasing out zinc oxide for young pigs

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has confirmed a previous decision to phase out zinc oxide. Consequently, the CVMP has once more recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

19-12-2016

Zinc oxide for young pigs to be phased out

Zinc oxide for young pigs to be phased out

The European Medicines Agency's Committee for Medicinal Products for Veterinary Use (CVMP) has recommended to the European Commission that medicinal products containing zinc oxide for the prevention of diarrhoea in young pigs should be withdrawn from the market.

Danish Medicines Agency

20-7-2016

Marketing authorisation for medicine for cows suspended in the EU/EEA

Marketing authorisation for medicine for cows suspended in the EU/EEA

On 14 July 2016, the Committee for Medicinal Products for Veterinary Use (CVMP) recommended that the marketing authorisation for the centrally authorised medicinal product Velactis (cabergoline) be suspended temporarily. Velactis is used to reduce milk production in dairy cows at the time of drying off. The recommendation follows reports of serious adverse events after treatment with Velactis.

Danish Medicines Agency

17-10-2014

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

PRAC recommends strengthening the restrictions on the use of valproate in women and girls

The EMA’s Pharmacovigilance and Risk Assessment Committee (PRAC) recommends strengthening the restrictions on the use of the antiepileptic valproate due to the risk of malformations and developmental problems in children exposed to valproate in the womb.

Danish Medicines Agency

3-10-2014

Consultation procedure about medicinal products and safety measure requirements not completed yet

Consultation procedure about medicinal products and safety measure requirements not completed yet

On 5 September 2014, the Danish Health and Medicines Authority submitted a draft list of the medicinal products comprised by the new safety measures rules (Directive 2001/83) for consultation. The consultation period expired on 17 September 2014, and on 3 October we were to inform the European Commission of the medicinal products we recommend including in the common EU lists. We have received 22 consultation responses. But on 24 September 2014 the European Commission amended the original guideline for...

Danish Medicines Agency

25-2-2014

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

EMA recommends further restrictions on the use of the osteoporosis medicine strontium ranelate (Protelos®)

The European Medicines Agency (EMA) recommends to restrict the use of the osteoporosis medicine strontium ranelate (Protelos®) to patients with severe osteoporosis who cannot be treated with other medicines approved for osteoporosis.

Danish Medicines Agency

27-3-2012

Illegal potency-enhancing drug in Denmark: Viamax Pure Power

Illegal potency-enhancing drug in Denmark: Viamax Pure Power

The Danish National Board of Health has received information about the dangerous potency-enhancing product Viamax Pure Power, which is sold by Danish online shops. Viamax Pure Power is not an authorised medicinal product, and we therefore warn consumers not to use the product. We advise consumers who have taken Viamax Pure Power to stop using it and to contact their doctor if they have any concerns. The illegal medicinal product may be handed over to a pharmacy for destruction.

Danish Medicines Agency

5-1-2012

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

Consultation on the Reimbursement Committee's recommendation concerning the reimbursement status of strong painkillers (opioids)

At the Danish Medicines Agency's request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N02A, opioids, as well as certain medicines in ATC groups N07BC and R05DA.

Danish Medicines Agency

3-1-2012

Danish Pharmacovigilance Update, 15 December 2011

Danish Pharmacovigilance Update, 15 December 2011

Among the topics covered in this issue of Danish Pharmacovigilance Update are: Atomoxetine (Strattera®) and the risk of increased blood pressure and heart rate, increased suspicion of risk of congenital malformations with the antiepileptic topiramate (Topimax® and others), and new recommendations for the antidepressant escitalopram.

Danish Medicines Agency

10-10-2018

If you use a #MedicalDevice affected by a power outage caused by #HurricaneMichael, check out the #FDA’s tips for using a generator to restore power to your device:  https://go.usa.gov/xPjau pic.twitter.com/SLxGKzIIgc

If you use a #MedicalDevice affected by a power outage caused by #HurricaneMichael, check out the #FDA’s tips for using a generator to restore power to your device: https://go.usa.gov/xPjau pic.twitter.com/SLxGKzIIgc

If you use a #MedicalDevice affected by a power outage caused by #HurricaneMichael, check out the #FDA’s tips for using a generator to restore power to your device: https://go.usa.gov/xPjau  pic.twitter.com/SLxGKzIIgc

FDA - U.S. Food and Drug Administration

9-10-2018

#ICYMI - FDA issues recommendations to help prevent surgical fires and      related patient injury. Click the link to read the recommendations:  https://go.usa.gov/xQdwG   #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

#ICYMI - FDA issues recommendations to help prevent surgical fires and related patient injury. Click the link to read the recommendations: https://go.usa.gov/xQdwG  #FirePreventionWeek #MedicalDevice

FDA - U.S. Food and Drug Administration

24-9-2018

If you use a #MedicalDevice affected by a power outage caused by #HurricaneFlorence, check out the #FDA’s tips for using a generator to restore power to your device:  https://go.usa.gov/xPjau pic.twitter.com/z8SW2mlb86

If you use a #MedicalDevice affected by a power outage caused by #HurricaneFlorence, check out the #FDA’s tips for using a generator to restore power to your device: https://go.usa.gov/xPjau pic.twitter.com/z8SW2mlb86

If you use a #MedicalDevice affected by a power outage caused by #HurricaneFlorence, check out the #FDA’s tips for using a generator to restore power to your device: https://go.usa.gov/xPjau  pic.twitter.com/z8SW2mlb86

FDA - U.S. Food and Drug Administration

21-9-2018

Click the link for a handy list of #FDA’s recommendations for using and  caring for your medical devices during a #hurricane.   https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

Click the link for a handy list of #FDA’s recommendations for using and caring for your medical devices during a #hurricane. https://go.usa.gov/xPbgc  #MedicalDevice

FDA - U.S. Food and Drug Administration

21-9-2018

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity

#DYK #hurricane season is active through November. Be prepared & stay informed of #MedicalDevice safety. Click the link to find a useful planning booklet from the #FDA that can help u prepare & handle power outages for medical devices that use electricity: https://go.usa.gov/xPbYt 

FDA - U.S. Food and Drug Administration

21-9-2018

Scientific guideline:  Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

Scientific guideline: Reflection paper on the use of aminopenicillins and their beta-lactamase inhibitor combinations in animals in the European Union: development of resistance and impact on human and animal health, draft: consultation open

The objective of this document is to review available information on the use of aminopenicillins and their beta-lactamase inhibitor combinations in veterinary medicines in the EU, their effect on the emergence of antimicrobial resistance (AMR) and the potential impact of resistance on human and animal health. The document provides information for the risk profiling, as recommended by the Antimicrobial Advice ad hoc Expert Group (AMEG) of the EMA.

Europe - EMA - European Medicines Agency

19-9-2018

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin  containing medical devices and device-led combination products to help  reduce the risk of patient injury. To read the guidance, click here:  https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/x

#FDA issues final guidance with recommendations for labeling and safety testing of #heparin containing medical devices and device-led combination products to help reduce the risk of patient injury. To read the guidance, click here: https://go.usa.gov/xP2VB  #MedicalDevice pic.twitter.com/hsdX5ylKPu

FDA - U.S. Food and Drug Administration

21-8-2018

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months!  https://go.usa.gov/xUskq 
#OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCarepic.twitter.com/VRDkVPvMTR

It’s #ContactLensHealthWeek! Remember to wear your contacts no longer than recommended and to replace your contact lens case once every 3 months! https://go.usa.gov/xUskq  #OnePairTakeCare pic.twitter.com/VRDkVPvMTR

FDA - U.S. Food and Drug Administration

6-8-2018

Scientific guideline:  ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

Scientific guideline: ICH M9 on biopharmaceutics classification system based biowaivers - Step 2b - First version, draft: consultation open

This new multidisciplinary guideline is proposed to address biopharmaceutics classification system (BCS)-based biowaivers. BCS-based biowaivers may be applicable to BCS Class I and III drugs, however BCS-based biowaivers for these two classes are not recognized worldwide. This means that pharmaceutical companies have to follow different approaches in the different regions. This guideline will provide recommendations to support the biopharmaceutics classification of medicinal products and will provide rec...

Europe - EMA - European Medicines Agency

18-7-2018

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity:  https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://hea

THREAD: We’re proud to work with the public-private Healthcare Sector Coordinating Council’s Medical Technology & Health IT Task Group to address @HHSgov Cybersecurity Task Force Report recommendations related to medical device cybersecurity: https://healthsectorcouncil.org/health-sector-mobilizes-against-cyber-threats/ …

FDA - U.S. Food and Drug Administration

16-7-2018

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Nexcyon Pharmaceuticals Ltd)

Reconcile (Active substance: Fluoxetine) - Centralised - Renewal - Commission Decision (2018)4770 of Mon, 16 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/V/C/133/R-18

Europe -DG Health and Food Safety

9-7-2018

Scientific guideline:  Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

Scientific guideline: Concept paper on the need to develop a reflection paper on development of medicinal products to prevent and treat acute kidney injury, draft: consultation open

The concept paper will include discussion of and recommendations for the requirements for evaluation and development of medicinal products for the prevention and/or treatment of acute kidney injury (AKI) and its long-term complications. Relevant topics for discussion include patient populations, endpoints, study methodology, and study duration.

Europe - EMA - European Medicines Agency

29-5-2018

FDA issues recommendations to help prevent surgical fires and related patient injury-  https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA issues recommendations to help prevent surgical fires and related patient injury- https://go.usa.gov/xQdwG  #MedicalDevice #Safety

FDA - U.S. Food and Drug Administration